APA

Poon E., Mullins S., Watkins A., Williams G. S., Koopmann J., Di Genova G., Cumberbatch M., Veldman-Jones M., Grosskurth S. E., Sah V., Schuller A., Reimer C., Dovedi S. J., Smith P. D., Stewart R. & Wilkinson R. W. (20180521). The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. : Journal for immunotherapy of cancer.

Chicago

Poon Edmund, Mullins Stefanie, Watkins Amanda, Williams Geoffrey S, Koopmann Jens-Oliver, Di Genova Gianfranco, Cumberbatch Marie, Veldman-Jones Margaret, Grosskurth Shaun E, Sah Vasu, Schuller Alwin, Reimer Corrine, Dovedi Simon J, Smith Paul D, Stewart Ross and Wilkinson Robert W. 20180521. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. : Journal for immunotherapy of cancer.

Harvard

Poon E., Mullins S., Watkins A., Williams G. S., Koopmann J., Di Genova G., Cumberbatch M., Veldman-Jones M., Grosskurth S. E., Sah V., Schuller A., Reimer C., Dovedi S. J., Smith P. D., Stewart R. and Wilkinson R. W. (20180521). The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. : Journal for immunotherapy of cancer.

MLA

Poon Edmund, Mullins Stefanie, Watkins Amanda, Williams Geoffrey S, Koopmann Jens-Oliver, Di Genova Gianfranco, Cumberbatch Marie, Veldman-Jones Margaret, Grosskurth Shaun E, Sah Vasu, Schuller Alwin, Reimer Corrine, Dovedi Simon J, Smith Paul D, Stewart Ross and Wilkinson Robert W. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment. : Journal for immunotherapy of cancer. 20180521.